Preferences for multipurpose technology and non-oral methods of antiretroviral therapy among women living with HIV in western Kenya: a survey study

Caitlin Bernard<sup>1</sup>, Beatrice Jakait<sup>2</sup>, William Fadel<sup>1</sup>, A. Mocello<sup>3</sup>, Maricianah Onono<sup>4</sup>, Elizabeth Bukusi<sup>4</sup>, Kara Wools-Kaloustian<sup>1</sup>, Craig Cohen<sup>3</sup>, and Rena Patel<sup>5</sup>

March 30, 2022

## Abstract

Objective: To understand the preferences of women living with HIV (WLHIV) for methods of multipurpose technology (MPT) for the co-administration of contraception and antiretroviral therapy (ART) and non-oral ART to guide their development and implementation. Design: A cross-sectional telephone survey as part of a study of pregnancy incidence among contraception and ART users Setting: Our study was performed in western Kenya Population: We included 1132 WLHIV of reproductive potential with prior experience using injectable and long-acting contraception Methods: We performed descriptive statistics and multinomial logistic regression Main Outcome Measures: Main outcomes were interest in MPT, important characteristics and preferred methods for MPT and non-oral ART, and predictors of interest in specific methods Results: Two-thirds (67%) reported interest in MPT, most commonly due to ease of using a single medication for both HIV treatment and pregnancy prevention (26%). Main reasons for lack of interest in MPT were need to stop/not use contraception while continuing ART (21%) and risk of side effects (16%). Preferred methods for MPT and non-oral ART were injectables (50%, 54%) and implants (32%, 31%). Prior use of a contraceptive implant or injectable predicted interest in similar methods for MPT and non-oral ART, and this did not vary by age. Conclusions: Many WLHIV in western Kenya are interested in MPT for contraception and ART. Prior experience with contraceptive implants and injectables predicts interest in similar methods of MPT and non-oral ART. Funding: NIH NIAID (K23AI120855) and the NIH NIAID, NICHD, NIDA, NCI, & NIMH for the EA-IeDEA Consortium (U01AI069911)

## Hosted file

MPT\_BJOG.pdf available at https://authorea.com/users/470597/articles/562641-preferences-for-multipurpose-technology-and-non-oral-methods-of-antiretroviral-therapy-among-women-living-with-hiv-in-western-kenya-a-survey-study

<sup>&</sup>lt;sup>1</sup>Indiana University School of Medicine

<sup>&</sup>lt;sup>2</sup>Moi Teaching and Referral Hospital

<sup>&</sup>lt;sup>3</sup>University of California San Francisco

<sup>&</sup>lt;sup>4</sup>Kenya Medical Research Institute

<sup>&</sup>lt;sup>5</sup>University of Washington Department of Medicine

Figure 1: Reported reasons for interest, lack of interest, and unsure interest in the use of multipurpose technology (MPT) for contraception and antiretroviral (ART) therapy among women of reproductive potential living with HIV (N=1132). Qualitative interpretation classified based on the analytic framework of Wyatt, et al. for the categorization of attributes influencing contraceptive choice.

Domain	Theme	Subthemes	Interested	Not Interested	Unsure of Interest
Mechanistic	User action	Ease of use	Easier to use if combined*	Easier to use if separate/confusion	
				in combined use	
		Probability of	Reduced method forgetfulness		
		omission Frequency of use	Less frequent use		
		Medication burden	Reduced medication burden	Increased medication burden	
	Ease of use	Convenience	Overall convenience		
		Method		Easier to use different methods of	
				ART & FP	
				Difficult to combine due to	
				different mechanisms of ART & FP	
	Return to fertility Combined effects	Reversibility	Benefit of combined effects (HIV	Need to stop FP & continue ART*  Different effects should not be	
Method Effect	Combined effects		treatment + pregnancy prevention)*	combined	
	Efficacy	Pregnancy	Prioritization of pregnancy prevention*		
		prevention	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			Better efficacy for pregnancy prevention		
		Combined efficacy	Better combined efficacy	Reduced combined efficacy	Unknown combined efficacy
	Side Effects		Fewer side effects	Greater/worse/different combined side effects*	Unknown combined side effects
			Hoping for fewer side effects	Personal or vicarious negative experience with FP side effects	
				· ·	
				Difficulty determining which medication is causing side effects	
		Reversibility		Difficulty in discontinuing/changing methods in case of side effects	
	Health benefits		Non-contraceptive health benefits		
Sodal/Normative	Partner Role			Lack of partner support	Need to consult partner
	Vicarious	Trying new things	Interest in trying new things		
	experience	HCW influence	Positive HCW influence	Fear of coercive FP use by HCW	Deferring to HCW
	Expectations	Lack of need for FP		Perceived lack of need for FP, but not wanting to be pregnant*	
				Desire to become pregnant*	
				Using abstinence or condoms as	
				primary FP method	
		Effect of FP use on behavior		Using FP promotes sexual promiscuity	
		Preferences		Prefer separate methods	Prefer separate methods
	Religion			Religion forbids FP use	
	Privacy		Concealability of ART &/or FP use		
Practical	Availability	Service Integration	Streamlined/integrated HIV + FP care*		
		User action	Reduced appointment forgetfulness		
	Time	Service	Service time-saving (reduced		
			appointment frequency/waiting time)		
		Method	Method use time-saving (reduced medication-taking)		
		Overall	Overall time-saving		
	Costs	Transport	Reduced transport cost		
		Overall	Overall reduced cost	Overall increased cost	

\*Most commonly reported reasons for interest, lack of interest and unsure interest within each domain ART = antivetrowiral therapy

FP = family planing (contraception)

HCW = health care worker